Tuberc Respir Dis.
2024 Apr;87(2):209-211. 10.4046/trd.2024.0010.
Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors’ Reply
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea
- 2Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
- 3Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea
- KMID: 2553782
- DOI: http://doi.org/10.4046/trd.2024.0010
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid
- Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
- Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
- Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
- Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
